Shots:
- The sNDA is based on the P-III ORIENT-15 clinical trial evaluates sintilimab + CT vs PBO + CT in a ratio (1:1) in 659 patients unresectable LA, recurrent or metastatic ESCC
- In an interim analysis, the therapy demonstrated an improvement in the 1EPs of OS & PFS. The results were presented at ESMO 2021
- Sintilimab is an innovative PD-1 inhibitor, jointly developed by Eli Lilly and Innovent. Additionally, Innovent has two regulatory submissions under review in China for sintilimab as 1L or 2L treatment of ESCC & NSCLC & is currently conducting 20+ clinical studies of sintilimab for multiple cancer
Click here to read full press release/ article | Ref: PR Newswire | Image: Innovent
The post Innovent Reports NMPA’s Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma first appeared on PharmaShots.
